High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
Title:
High response rate and improved exercise capacity and quality of life with a new regimen of darbepoetin alfa with or without filgrastim in lower-risk myelodysplastic syndromes: a phase II study by the GFM
Author:
Kelaidi, C. Beyne-Rauzy, O. Braun, T. Sapena, R. Cougoul, P. Adès, L. Pillard, F. Lambert, C. Charniot, J. C. Guerci, A. Choufi, B. Stamatoullas, A. Slama, B. Renzis, B. De Ame, S. Damaj, G. Boyer, F. Chaury, M. P. Legros, L. Cheze, S. Testu, A. Gyan, E. Béné, M. C. Rose, C. Dreyfus, F. Fenaux, P.